SAMRA AMAN: Open Payments
NPI 1417677238 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$556 in 29 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $215 · 2025 $556
Food & beverage: $556
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 5 | $117 |
| ABBVIE INC. | 5 | $101 |
| Novo Nordisk Inc | 4 | $73 |
| Lilly USA, LLC | 4 | $71 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $30 |
| Novartis Pharmaceuticals Corporation | 1 | $24 |
| SANOFI-AVENTIS U.S. LLC | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Dynavax Technologies Corporation | 1 | $19 |
Products named: PREVNAR 20, Wegovy, MOUNJARO, QULIPTA, UBRELVY, AIRSUPRA, XIFAXAN, LEQVIO.
Industry payments across TX — which companies pay providers there.
